ClinicalTrials.gg
CompletedNCT03486392Updated Feb 5, 2020Results posted

A Study to Evaluate the Safety and Efficacy of JNJ-64565111 in Non-diabetic Severely Obese Participants

A Phase 2 interventional study of JNJ-64565111 Dose Level 1 and JNJ-64565111 Dose Level 2 in Obesity, sponsored by Janssen Research & Development, LLC. Completed at 51 sites in 6 countries. Open to participants aged 18 Years to 70 Years. Per ClinicalTrials.gov, last updated 2020-02-05.

Sponsored by Janssen Research & Development, LLC (part of Johnson & Johnson) · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
474
Allocation
Randomized
Ages
18 Years to 70 Years
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-16

Among 35 studies in Obesity by Johnson & Johnson — none open to participants now, none under way, none of them phase 3. Obesity · Johnson & Johnson.

Enrollment
5th of 31
474 · median 113
Started
2018
with 2 others
Phase 2
10 of 35
none open now
Registered
32nd of 35
by date

Among the 35 studies in Obesity by Johnson & Johnson, this one is the 5th largest by enrollment of the 31 interventional ones that give a count, is one of 3 that started in 2018, is one of 10 in phase 2, and was the 32nd registered.

Obesity

11,543 studies on the registry are indexed under Obesity; 2,042 are open to participants now.

Browse Obesity studies →

Open to participants now

None of the 35 studies in Obesity by Johnson & Johnson is open now. The open studies under Obesity, anywhere →

Who these studies take

Of the 1,339 Obesity studies recruiting now, 377 (28%) set no upper age limit and 859 (64%) stop at 75 or younger; 167 take children under 18; 490 take healthy volunteers.

This study: 18 Years to 70 Years · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Download CSVNarrow it in search →With an account: the 35 studies in Obesity by Johnson & Johnson as a file.
02

Study summary

The purpose of this study is to assess the effects of JNJ-64565111 compared with placebo after 26 weeks of treatment on the percent change in body weight from baseline and to assess the safety and tolerability, in non-diabetic severely obese participants.

03

Conditions studied

  • Obesity

Browse trials for

04

Who can participate

Ages eligible
18 Years to 70 Years
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • (BMI) greater than or equal to (>=) 35 to less than or equal to (\<=) 50 kilogram per square meter (kg/m\^2) at the screening visit
  • Stable weight (that is, change of \<= 5 percent [%] within 12 weeks before screening based on medical history)
  • Women must be either: (a) , or (b) Permanently sterilized or otherwise be incapable of pregnancy, or (c) Heterosexually active and practicing a highly effective method of , or (d) Not heterosexually active
  • Woman of have a negative pregnancy test at screening
  • Willing and able to adhere to specific the prohibitions and restrictions

Exclusion criteria

Exclusion Criteria:

  • History of obesity with a known secondary cause (for example, Cushing's disease/syndrome)
  • History of Type 1 diabetes mellitus, Type 2 diabetes mellitus (T2DM), diabetic ketoacidosis (DKA), pancreas or beta-cell transplantation, or diabetes secondary to pancreatitis or pancreatectomy
  • Has a (HbA1c) of >= 6.5% or fasting plasma glucose (FPG) >= 126 milligrams per deciliter (mg/dL) (>= 7.0 millimoles per liter [mmol/L]) at screening
  • Screening calcitonin of >= 50 picograms per milliliter (pg/mL) personal history or family history of medullary thyroid cancer, or of multiple endocrine neoplasia syndrome type 2 (MEN 2), regardless of time prior to screening
  • History of glucagonoma
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

BMI (body mass index)

Weight in kilograms divided by height in metres squared. Example: 70 kg and 1.75 m gives 70 ÷ (1.75 × 1.75) ≈ 22.9.

What counts as overweight or obesity differs between countries (some use lower cut-offs), so go by the range the study states.

Postmenopausal

Periods have stopped for good: usually no period for 12 months in a row without another medical reason, sometimes confirmed by a blood test (FSH).

Contraception

Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.

Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

HbA1c

A blood test of average blood sugar over the past two to three months, given as a percentage or in mmol/mol. 6.5% (48 mmol/mol) or more is the usual threshold for diabetes, normally confirmed by a second test.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
Double (Participant, Investigator)
Enrollment
474 participants (actual)

Study arms

  • Experimental
    Double-Blind: JNJ-64565111 Dose Level 1

    Participants will receive a JNJ-64565111 Dose Level 1 subcutaneously (SC) once-weekly for 26-week treatment phase.

    Drug: JNJ-64565111 Dose Level 1

  • Experimental
    Double-Blind: JNJ-64565111 Dose Level 2

    Participants will receive a JNJ-64565111 Dose Level 2 SC once-weekly for 26-week treatment phase.

    Drug: JNJ-64565111 Dose Level 2

  • Experimental
    Double-Blind: JNJ-64565111 Dose Level 3

    Participants will receive a JNJ-64565111 Dose Level 3 SC once-weekly for 26-week treatment phase.

    Drug: JNJ-64565111 Dose Level 3

  • Placebo comparator
    Double-Blind: Placebo

    Participants will receive placebo matching to JNJ-64565111 SC once-weekly for 26-week treatment phase.

    Drug: Placebo

  • Active comparator
    Open-Label: 3.0 milligram (mg) Liraglutide

    Participant will receive once-daily doses of 0.6, 1.2, 1.8, 2.4, or 3.0 mg. The participants will receive liraglutide at a starting dose of 0.6 mg SC once-daily on Day 1. Participants will be instructed to increase the dose of liraglutide by 0.6 mg dose increment every 7 days, up to the full dosage of 3.0 mg by Week 5. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.

    Drug: Liraglutide

Interventions

  • Participants will receive JNJ-64565111 Dose Level 1 SC once -weekly until Week 26.

  • Participants will receive JNJ-64565111 Dose Level 2 SC once-weekly until Week 26.

  • Participants will receive JNJ-64565111 Dose Level 3 SC once-weekly until Week 26.

  • Participants will receive liraglutide at a starting dose of 0.6 mg then dose will be ramped up by 0.6 mg daily until reaching 3.0 mg. Participants will then continue on the 3.0 mg once-daily dosage until Week 26.

    Also known as: Saxenda

  • DrugPlacebo

    Participants will receive matching placebo SC once-weekly until Week 26.

06

What researchers measure

Primary outcomes

  1. Percent Change From Baseline in Body Weight at Week 26

    Percent change in body weight in kilograms (kg) from baseline to Week 26 was reported.

    Time frame: Baseline, Week 26

  2. Number of Participants With Treatment Emergent Adverse Events (TEAEs)

    An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE was defined as an AE with an onset after the initiation study drug and before the last study drug date of the double-blind (26-week) treatment phase for plus 28 days for liraglutide participants, and plus 35 days for JNJ-64565111 and placebo participants.

    Time frame: Up to Week 30

Secondary outcomes

  1. Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Body Weight Loss at Week 26

    Number of participants with \>= 5% body weight loss from baseline to Week 26 were reported.

    Time frame: Week 26

  2. Number of Participants With Greater Than or Equal to 10 % Body Weight Loss at Week 26

    Number of participants with \>= 10 % body weight loss from baseline to Week 26 were reported.

    Time frame: Week 26

  3. Change From Baseline in Body Weight at Week 26

    Change from baseline in body weight at Week 26 was reported.

    Time frame: Baseline, Week 26

07

Results

Posted Feb 5, 2020

Participant flow

Participant flow — Overall Study
MilestoneDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
Started6059118118119
Completed5759104109115
Not completed301494
Withdrew: Lost to follow-up00852
Withdrew: Withdrawal by subject30641
Withdrew: Death00001

Outcome measures

PrimaryPercent Change From Baseline in Body Weight at Week 26

Percent change in body weight in kilograms (kg) from baseline to Week 26 was reported.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · Percent Change
Percent Change From Baseline in Body Weight at Week 26
Percent ChangeDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
Percent Change From Baseline in Body Weight at Week 26-1.76 ± 0.73-8.51 ± 0.76-9.83 ± 0.56-11.80 ± 0.58-7.54 ± 0.54
Statistical analysis
  • Double Blind: Placebo vs Double Blind: JNJ-64565111 5.0 mg · Dunnett's method · p = < 0.001 · Difference of least square (ls) means: -6.75 · 95% CI -9.31 to -4.19
  • Double Blind: Placebo vs Double Blind: JNJ-64565111 7.4 mg · Dunnett's method · p = < 0.001 · Difference of ls means: -8.07 · 95% CI -10.31 to -5.84
  • Double Blind: Placebo vs Double Blind: JNJ-64565111 10.0 mg · Dunnett's method · p = < 0.001 · Difference of ls means: -10.04 · 95% CI -12.31 to -7.78
  • Double Blind: Placebo vs Open Label: Liraglutide 3.0 mg · Dunnett's method · p = < 0.001 · Difference of ls means: -5.78 · 95% CI -7.99 to -3.57
PrimaryNumber of Participants With Treatment Emergent Adverse Events (TEAEs)

An adverse event (AE) is any untoward medical occurrence in a clinical study participant administered a medicinal (investigational or non-investigational) product. An AE does not necessarily have a causal relationship with the treatment. An AE can therefore be any unfavorable and unintended sign (including an abnormal finding), symptom, or disease temporally associated with the use of a medicinal (investigational or non-investigational) product, whether or not related to that medicinal (investigational or non-investigational) product. A TEAE was defined as an AE with an onset after the initiation study drug and before the last study drug date of the double-blind (26-week) treatment phase for plus 28 days for liraglutide participants, and plus 35 days for JNJ-64565111 and placebo participants.

Time frame:
Up to Week 30
Reported as:
Count of participants · Participants
Number of Participants With Treatment Emergent Adverse Events (TEAEs)
ParticipantsDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
Number of Participants With Treatment Emergent Adverse Events (TEAEs)435311011096
SecondaryNumber of Participants With Greater Than or Equal to (>=) 5 Percent (%) Body Weight Loss at Week 26

Number of participants with \>= 5% body weight loss from baseline to Week 26 were reported.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Body Weight Loss at Week 26
ParticipantsDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
Number of Participants With Greater Than or Equal to (>=) 5 Percent (%) Body Weight Loss at Week 26834706256
SecondaryNumber of Participants With Greater Than or Equal to 10 % Body Weight Loss at Week 26

Number of participants with \>= 10 % body weight loss from baseline to Week 26 were reported.

Time frame:
Week 26
Reported as:
Count of participants · Participants
Number of Participants With Greater Than or Equal to 10 % Body Weight Loss at Week 26
ParticipantsDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
Number of Participants With Greater Than or Equal to 10 % Body Weight Loss at Week 26223434627
SecondaryChange From Baseline in Body Weight at Week 26

Change from baseline in body weight at Week 26 was reported.

Time frame:
Baseline, Week 26
Reported as:
Least squares mean · kg
Change From Baseline in Body Weight at Week 26
kgDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
Change From Baseline in Body Weight at Week 26-2.05 ± 0.827-9.58 ± 0.861-11.07 ± 0.633-13.23 ± 0.656-8.32 ± 0.610

Adverse events

Collected over Up to 30 Weeks. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Double Blind: Placebo0/60 (0%)4/60 (6.7%)33/60 (55%)
Double Blind: JNJ-64565111 5.0 mg0/59 (0%)3/59 (5.1%)43/59 (72.9%)
Double Blind: JNJ-64565111 7.4 mg0/118 (0%)2/118 (1.7%)106/118 (89.8%)
Double Blind: JNJ-64565111 10.0 mg0/118 (0%)4/118 (3.4%)104/118 (88.1%)
Open Label: Liraglutide 3.0 mg1/119 (0.8%)4/119 (3.4%)81/119 (68.1%)
Most frequent serious events
Showing 10 of 16
Most frequent serious events
EventDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
IleusGastrointestinal disorders0/601/590/1180/1180/119
VomitingGastrointestinal disorders0/600/591/1182/1180/119
Biliary ColicHepatobiliary disorders0/601/590/1180/1181/119
Abortion SpontaneousPregnancy, puerperium and perinatal conditions0/601/590/1180/1180/119
Umbilical HerniaGastrointestinal disorders1/600/590/1180/1180/119
ObesityMetabolism and nutrition disorders1/600/590/1180/1180/119
OsteoarthritisMusculoskeletal and connective tissue disorders1/600/590/1180/1180/119
MenorrhagiaReproductive system and breast disorders1/600/590/1180/1180/119
Stress CardiomyopathyCardiac disorders0/600/591/1180/1180/119
PneumoniaInfections and infestations0/600/590/1181/1180/119
Most frequent other events
Showing 10 of 23
Most frequent other events
EventDouble Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mg
NauseaGastrointestinal disorders4/6030/5980/11879/11848/119
VomitingGastrointestinal disorders0/6012/5947/11864/11820/119
DiarrhoeaGastrointestinal disorders3/608/5924/11823/11827/119
ConstipationGastrointestinal disorders3/607/5920/11821/11820/119
Decreased AppetiteMetabolism and nutrition disorders1/6010/5916/11820/11810/119
HeadacheNervous system disorders6/607/5920/1188/1189/119
DyspepsiaGastrointestinal disorders2/605/5918/11813/1189/119
NasopharyngitisInfections and infestations9/605/5911/1186/11810/119
FatigueGeneral disorders2/607/5915/11817/1185/119
EructationGastrointestinal disorders0/604/5914/11816/1185/119

Baseline characteristics

Age, Continuous
Age, Continuous(years)Double Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mgTotal
Mean46.9 ± 11.8447.3 ± 11.1846.2 ± 11.6846.2 ± 12.1645.6 ± 11.7146.3 ± 11.73
Sex: Female, Male
Sex: Female, Male(Participants)Double Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mgTotal
Female4847868689356
Male1212323230118
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)Double Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mgTotal
Hispanic or Latino359111442
Not Hispanic or Latino5754108107105431
Unknown or Not Reported001001
Race (NIH/OMB)
Race (NIH/OMB)(Participants)Double Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mgTotal
American Indian or Alaska Native000011
Asian101136
Native Hawaiian or Other Pacific Islander000314
Black or African American8388734
White5156106103105421
More than one race002215
Unknown or Not Reported001113
Region of Enrollment
Region of Enrollment(Participants)Double Blind: PlaceboDouble Blind: JNJ-64565111 5.0 mgDouble Blind: JNJ-64565111 7.4 mgDouble Blind: JNJ-64565111 10.0 mgOpen Label: Liraglutide 3.0 mgTotal
BELGIUM7515131858
CANADA9812171662
POLAND8614181561
SWEDEN121422191481
UNITED KINGDOM5817111758
UNITED STATES1918384039154
08

Study locations

51 sites
  • Central Phoenix Medical Clinic
    Phoenix, Arizona 85020, United States
  • Diablo Clinical Research, Inc.
    Walnut Creek, California 94598, United States
  • Care Partners Clinical Research
    Jacksonville, Florida 32277, United States
  • Advanced Clinical Research
    Boise, Idaho 83642, United States
  • Medisphere Medical Research Center, Llc
    Evansville, Indiana 47714, United States
  • L-Marc Research Center
    Louisville, Kentucky 40213, United States
  • Milford Emergency Associates, Inc.
    Marlborough, Massachusetts 01752, United States
  • Central New York Clinical Research
    Manlius, New York 13104, United States
  • Weill Cornell Medicine
    New York, New York 10065, United States
  • Rapid Medical Research
    Cleveland, Ohio 44122, United States
  • Omega Medical Research
    Warwick, Rhode Island 02886, United States
  • Coastal Carolina Research Center
    Mount Pleasant, South Carolina 29464, United States
  • Dallas Diabetes Research Center
    Dallas, Texas 75230, United States
  • Permian Research Foundation
    Odessa, Texas 79761, United States
  • Advanced Clinical Research
    West Jordan, Utah 84088, United States
  • Rainier Clinical Research Center
    Renton, Washington 98057, United States
  • Allegiance Reserach Specialists, LLC
    Wauwatosa, Wisconsin 53226, United States
  • OLV Ziekenhuis Aalst
    Aalst, 9300, Belgium
  • CSL Arlon
    Arlon, 6700, Belgium
  • UZ Antwerpen
    Edegem, 2650, Belgium
  • UZ Leuven
    Leuven, 3000, Belgium
  • CHU de Liège
    Liège, 4000, Belgium
  • AZ Delta
    Roeselare, 8800, Belgium
  • AZ Glorieux Ronse
    Ronse, 9600, Belgium
  • Practimed Medical Center
    Tessenderlo, 3980, Belgium
  • Joanne F. Liutkus Medicine Professional Corporation
    Cambridge, Ontario N1R 7L6, Canada
  • Canadian Phase Onward
    Toronto, Ontario M3J 2C5, Canada
  • Dr. Anil K Gupta Medicine Professional Corporation
    Toronto, Ontario M9V 4B4, Canada
  • Manna Research
    Toronto, Ontario M9W 4L6, Canada
  • Manna Research
    Levis, Quebec G6W 0M5, Canada
  • Manna Research
    Pointe Claire, Quebec H9R 4S3, Canada
  • Clinique des Maladies Lipidiques de Québec
    Québec, Quebec G1V 4W2, Canada
  • Indywidualna Praktyka Lekarska, Gabinet Leczenia Otyłości i Chorób Dietozależnych
    Białystok, 15-281, Poland
  • Centrum Badań Klinicznych PI-House sp. z o.o.
    Gdańsk, 80-546, Poland
  • Nzoz Salvia
    Katowice-Ligota, 40-752, Poland
  • NZOZ 'Linia' Centrum Leczenia Zaburzeń Metabolicznych Magdalena Olszanecka-Glinianowicz
    Katowice, 40-767, Poland
  • Centrum Zdrowia Metabolicznego Paweł Bogdański
    Poznan, 60-589, Poland
  • Katarina Berndtsson-Blom Ladulaaskliniken
    Borås, 50630, Sweden
  • PTC,Primary care Trial Center
    Goteborg, 42144, Sweden
  • Intern Medicin
    Göteborg, 41345, Sweden
  • PharmaSite
    Helsingborg, 25220, Sweden
  • PharmaSite
    Malmo, 21152, Sweden
  • PTC- Skaraborg
    Skövde, 541 50, Sweden
  • Avdelningen för kliniska prövningar
    Örebro, 701 85, Sweden
  • Southmead Hospital
    Bristol, BS10 5NB, United Kingdom
  • Ashgate Medical Practice
    Chesterfield, S40 4AA, United Kingdom
  • Hathaway Medical Centre
    Chippenham, SN14 6GT, United Kingdom
  • Aintree University Hospital NHS Trust
    Liverpool, L9 7AL, United Kingdom
  • Clifton Medical Centre
    Rotherham, S65 1DA, United Kingdom
  • Albany House Medical Centre
    Wellingborough, NN8 4RW, United Kingdom
  • Bradford on Avon and Melksham Health Partnership
    Wiltshire, BA15 1DQ, United Kingdom
09

References and documents

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Ran from Mar 2018 to primary completion in Mar 2019, 11 months.

Results were first posted in Feb 2020, 10 months after primary completion.

Of 176 industry-sponsored phase 2 interventional studies under Obesity, half reached primary completion within 12 months of starting (the median), counting those still running; a quarter within 8 and three quarters within 18. This study's 11 months is close to that.

Counting every sponsor, half of 307 studies reached it within 16 months; a quarter within 10 and three quarters within 35.

How these figures are worked out, and which studies are left out of them.

Registered
Mar 23, 2018
First posted
Apr 3, 2018
StartActual
Mar 26, 2018
Primary completionActual
Mar 8, 2019
CompletionActual
Mar 8, 2019
Results first posted
Feb 5, 2020
Last update
Feb 5, 2020
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Feb 5, 2020, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT03486392
Responsible party
Sponsor
First posted
Apr 3, 2018
Start date
Mar 26, 2018
Primary completion
Mar 8, 2019
Completion
Mar 8, 2019
Results posted
Feb 5, 2020
Last update
Feb 5, 2020

Study contacts

Janssen Research & Development, LLC Clinical Trial
study director · Janssen Research & Development, LLC

Oversight

Data monitoring committee
Yes
FDA-regulated drug
Yes
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Jan 2020. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drug tested here: Efinopegdutide

Start the discussion